As of July 31, 2025, Hester Biosciences Ltd is trading near ₹1,950 after a recent rebound, though it has experienced a significant decline over the past year, down roughly 37% from its 52-week high above ₹3,250. The stock’s recovery in the last three months has been moderate, with gains of about 9%, and short-term sentiment appears slightly positive given the recent upward movement.
The company’s current price-to-earnings ratio is elevated, close to 58, and the price-to-book ratio is about 4.9, indicating a premium valuation compared to its book value. Hester Biosciences maintains a market capitalization near ₹1,650 crore, placing it among smaller specialty pharma and agri-biotech firms. While the core fundamentals show resilience, the firm recently reported a contraction in sales for the first time in three years, which led to some investor caution.
Technically, Hester Biosciences is recovering from its yearly lows near ₹1,240 and is showing renewed buying interest at current levels, confirmed by an uptick in volumes and momentum. However, given the sharply reduced returns over the past year, sentiment is mixed, and further upside will likely depend on improvement in financial result trends and any breakout above resistance points established during its downtrend.
Overall, the near-term outlook is cautiously constructive with recent stabilization, but investors should monitor for sustained improvements in revenue and earnings to confirm a continued reversal.
The company’s current price-to-earnings ratio is elevated, close to 58, and the price-to-book ratio is about 4.9, indicating a premium valuation compared to its book value. Hester Biosciences maintains a market capitalization near ₹1,650 crore, placing it among smaller specialty pharma and agri-biotech firms. While the core fundamentals show resilience, the firm recently reported a contraction in sales for the first time in three years, which led to some investor caution.
Technically, Hester Biosciences is recovering from its yearly lows near ₹1,240 and is showing renewed buying interest at current levels, confirmed by an uptick in volumes and momentum. However, given the sharply reduced returns over the past year, sentiment is mixed, and further upside will likely depend on improvement in financial result trends and any breakout above resistance points established during its downtrend.
Overall, the near-term outlook is cautiously constructive with recent stabilization, but investors should monitor for sustained improvements in revenue and earnings to confirm a continued reversal.
Trade active
20%+ Move in a day almost 3 years FD renewed in a day
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.